Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative Disease and Viral Infection Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DNAJC5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DNAJC5 Recombinant Protein (Wild Type & L115R Mutant) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View DNAJC5 Products |
| Gene Delivery | DNAJC5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional assays. |
View DNAJC5 Products |
| Benchmark Ab | Anti-DNAJC5 Recombinant Antibody High-affinity positive control for immunoprecipitation and western blot. |
View DNAJC5 Products |
| Validator | DNAJC5 siRNA Set Target-specific knockdown verification in cell-based models. |
View DNAJC5 Products |
| Related Target A | HSPA8 (Hsc70) Primary co-chaperone partner; critical for validating DNAJC5 complex disruption. |
View HSPA8 Products |
| Related Target B | MAPT (Tau) DNAJC5 regulates the atypical secretion and propagation of Tau aggregates. |
View MAPT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Disruption of DNAJC5-HSPA8 protein-protein interaction | High-purity, low-endotoxin recombinant proteins ensuring low background in HTRF/AlphaLISA assays |
| Mutant-specific drug screening (ANCL-associated L115R/L116del) | Sequence-verified mutant recombinant proteins for comparative binding and stability profiling |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in Phenotypic Screens | Validated siRNA included for specificity checks |
Live DNAJC5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DNAJC5 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule protein-protein interaction (PPI) inhibitors and genetic medicines (siRNA/ASO). As first-generation therapies reach the clinic, the next wave of R&D is targeting mutant-selective degradation and the inhibition of extracellular vesicle-mediated pathogenic protein propagation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI) | Academic Spin-offs, Neuro-biotechs | Alzheimer's, Parkinson's Disease | Binding Assay (Need high-purity WT/Mutant DNAJC5 and HSPA8) |
| siRNA / ASO | RNAi Therapeutics Developers | Adult Neuronal Ceroid Lipofuscinosis (ANCL) | Knockdown validation (Need validated DNAJC5 siRNA & Lentivirus) |
| Gene Therapy | Rare Disease Consortia | Kufs Disease (ANCL) | Overexpression verification (Need stable Lentivirus particles) |